Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.51 |
| ▸ | ATF1 | P18846 | 2/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.50 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | JUN | P05412 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804497 | 0.87 | PTGES (0.52) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL24682601 | 0.87 | PTGES (0.52) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL1585024 | 0.86 | NFKB1 (0.52) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL28049181 | 0.83 | KCNQ3 (0.50) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL21906016 | 0.82 | SCN10A (0.68) | SCN10AJAK2JAK1TYK2SORT1 | |
| SCHEMBL28049179 | 0.81 | KCNQ3 (0.48) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29732883 | 0.80 | P2RX1 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL28789750 | 0.80 | P2RX1 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL5414532 | 0.80 | P2RX1 (0.64) | NFKB1ATF1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL22435417 | 0.79 | CYP1A2 (0.50) | NFKB1ATF1KITJUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | P2RX5, HRH4, TRPV1 | NFKB1 1918/4885ATF1 1889/4885KCNQ3 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.